March 2017

Sekisui Turns 70 This Month!

Author:  Michael Millhollen
Posted:  03 March 2017

From a single plastics manufacturing plant in Japan to a diverse, multi-billion-dollar, global family which includes Sekisui XenoTech in Kansas City, Sekisui Chemical Group has positioned itself as a corporate leader in key industries and a strong advocate for environmental issues.
 
The Japanese company was founded as a general plastics manufacturing business in March 1947. Throughout the 1950s, the company continued to expand with new products, technologies and facilities. In April 1963, then “Sekisui Plastics Corporation” became the first Japanese company to open a manufacturing facility in the United States (Hazelton, PA).
 
Over the next four decades, the company charted growth in new technologies and established a presence around the world. In 2006, Daiichi Pure Chemicals Co., Ltd. was acquired and Sekisui Medical Co., Ltd. was established in 2008 as part of the company's Medical Division to focus on the advancement of new therapeutic research in human, animal and environmental science. Later that same year, XenoTech, LLC was acquired to bring focused expertise on biotransformation and preclinical development consulting to the broad range of pharmaceutical development services offered by Sekisui.
 
XenoTech was founded in 1994 to provide scientists and pharmaceutical researchers with the finest tools and resources needed to advance the development of safer drugs. From a small laboratory at the University of Kansas Medical Center in the 1980s, Sekisui XenoTech grew to become a trusted partner and expert consultant to 35 of the top 40 pharmaceutical companies worldwide, as well as numerous biotech, small, medium and virtual pharma entities and institutions. Sekisui XenoTech is 1 of 11 subsidiaries that are a part of Sekisui America Corporation, which represents Sekisui Chemical Group in North America and supports each Group company by providing reliable resources and assets. This alignment has allowed Sekisui XenoTech to offer a comprehensive range of products and services to accelerate drug development, globally.

Comments
Blog post currently doesn't have any comments.
Give Feedback